CytoMed Therapeutics’ Chairman’s Effective Shareholding Climbs to 21.95%
SINGAPORE, Oct. 22, 2025 — CytoMed Therapeutics (NASDAQ: GDTC) (“CytoMed” or the “Company”), a clinical-stage biopharmaceutical firm based in Singapore that specializes in developing affordable, donor-derived cell-based immunotherapies for a broad spectrum of cancers, including both blood and solid tumors,
More